Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy Meeting Abstract
| Authors: | Bryce, A. H.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; McDermott, R. S.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Abida, W.; Daugaard, G.; Heidenreich, A.; Krieger, L. E. M.; Sautois, B.; Loehr, A.; Despain, D.; Go, J.; Watkins, S. P.; Chowdhury, S.; Ryan, C. J.; Fizazi, K. |
| Abstract Title: | Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.18 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 18 -- Source: Cinahl |
